Objective To explore the efficacy of DSA-guided intrathecal drug delivery system combined with Zi Wu Liu Zhu Acupoint Therapy for management of cancer pain and provide reference for its standardized clinical application.Methods and Results Recommendations were formulated based on literature review and expert group discussion,and consensus was reached following expert consultation.The consensus recommendations are comprehensive,covering the entire treatment procedures from preoperative assessment and preparation,surgical operation process,postoperative management and traditional Chinese medicine treatment to individualized treatment planning.The study results showed that the treatment plans combining traditional Chinese with Western medicine effectively alleviated cancer pain,reduced the use of opioid drugs,and significantly improved the quality of life and enhanced immune function of the patients.Postoperative follow-up suggested good treatment tolerance among the patients without serious complications.Conclusion The formulated consensus is comprehensive and can provide reference for clinicians to use DSA-guided intrathecal drug delivery system combined with Zi Wu Liu Zhu Acupoint Therapy.The combined treatment has a high clinical value with a good safety profile for management of cancer pain.

Objective:To investigate the therapeutic effects of fluticasone propionate combined with loratadine syrup and montelukast sodium on asthma and allergic rhinitis in children.Methods:A total of 119 children with asthma and allergic rhinitis, admitted to Department of Pediatrics, Dongyang Maternal and Child Health Hospital from March 2021 to March 2024, were selected for this retrospective study. Based on the different treatment methods recorded in the medical record system, the children were divided into two groups: the control group ( n = 70), which received loratadine syrup combined with montelukast sodium, and the observation group ( n = 49), which received fluticasone propionate combined with loratadine syrup and montelukast sodium. Clinical symptoms (rhinitis and asthma), serum markers (immunoglobulin E, interleukin-4, and interleukin-6), lung function (maximum peak expiratory flow rate, forced expiratory volume in the first second, forced expiratory flow at 25% of vital capacity, forced expiratory flow at 50% of vital capacity, forced expiratory flow at 75% of vital capacity), as well as adverse reactions and clinical efficacy, were observed and compared between the two groups. Results:After treatment, the symptom scores for both rhinitis and asthma in the observation group were significantly lower than those in the control group [(3.65 ± 0.88) vs. (4.55 ± 1.06), t = 4.88, P < 0.001; (2.15 ± 0.56) vs. (3.28 ± 0.89), t = 7.86, P < 0.001]. The levels of immunoglobulin E, interleukin-4, and interleukin-6 in the observation group were significantly lower than those in the control group [(0.31 ± 0.18) g/L vs. (0.42 ± 0.19) g/L, t = 3.18, P = 0.002; (56.83 ± 8.25) ng/L vs. (62.16 ± 9.94) ng/L, t = 3.08, P = 0.003; (32.48 ± 3.11) ng/L vs. (39.61 ± 4.72) ng/L, t = 9.26, P < 0.001]. The values for forced expiratory volume in the first second and forced expiratory flow at 25%, 50%, and 75% of vital capacity in the observation group were significantly higher than those in the control group [(87.18 ± 5.15)% vs. (84.36 ± 4.68)%, t = 3.10, P = 0.002; (89.35 ± 3.88)% vs. (83.25 ± 3.56)%, t = 8.86, P < 0.001; (74.36 ± 6.65)% vs. (65.25 ± 5.36)%, t = 8.26, P < 0.001; (71.68 ± 8.76)% vs. (65.35 ± 7.86)%, t = 4.12, P < 0.001; (69.24 ± 4.38)% vs. (65.35 ± 2.43)%, t = 6.20, P < 0.001]. The incidence of adverse reactions was significantly higher in the observation group than in the control group [8.16% (4/49) vs. 4.29% (3/70), χ2 = 0.60, P = 0.439]. The overall response rate was significantly higher in the observation group than in the control group [95.92% (47/49) vs. 82.86% (58/70), χ2 = 5.26, P = 0.022]. Conclusions:Fluticasone propionate combined with loratadine syrup and montelukast sodium can effectively alleviate symptoms in children with asthma and allergic rhinitis, improve serum indicators, enhance lung function, and increase clinical efficacy without substantially increasing adverse reactions, demonstrating high safety.

OBJECTIVES: To explore the efficacy of DSA-guided intrathecal drug delivery system combined with Zi Wu Liu Zhu Acupoint Therapy for management of cancer pain and provide reference for its standardized clinical application. Methods and. RESULTS: Recommendations were formulated based on literature review and expert group discussion, and consensus was reached following expert consultation. The consensus recommendations are comprehensive, covering the entire treatment procedures from preoperative assessment and preparation, surgical operation process, postoperative management and traditional Chinese medicine treatment to individualized treatment planning. The study results showed that the treatment plans combining traditional Chinese with Western medicine effectively alleviated cancer pain, reduced the use of opioid drugs, and significantly improved the quality of life and enhanced immune function of the patients. Postoperative follow-up suggested good treatment tolerance among the patients without serious complications. CONCLUSIONS The formulated consensus is comprehensive and can provide reference for clinicians to use DSA-guided intrathecal drug delivery system combined with Zi Wu Liu Zhu Acupoint Therapy. The combined treatment has a high clinical value with a good safety profile for management of cancer pain.
Humans ; Medicine, Chinese Traditional ; Cancer Pain/therapy* ; Drugs, Chinese Herbal/therapeutic use* ; Drug Delivery Systems ; Pain Management/methods* ; China

Objective:To investigate the therapeutic effects of fluticasone propionate combined with loratadine syrup and montelukast sodium on asthma and allergic rhinitis in children.Methods:A total of 119 children with asthma and allergic rhinitis, admitted to Department of Pediatrics, Dongyang Maternal and Child Health Hospital from March 2021 to March 2024, were selected for this retrospective study. Based on the different treatment methods recorded in the medical record system, the children were divided into two groups: the control group ( n = 70), which received loratadine syrup combined with montelukast sodium, and the observation group ( n = 49), which received fluticasone propionate combined with loratadine syrup and montelukast sodium. Clinical symptoms (rhinitis and asthma), serum markers (immunoglobulin E, interleukin-4, and interleukin-6), lung function (maximum peak expiratory flow rate, forced expiratory volume in the first second, forced expiratory flow at 25% of vital capacity, forced expiratory flow at 50% of vital capacity, forced expiratory flow at 75% of vital capacity), as well as adverse reactions and clinical efficacy, were observed and compared between the two groups. Results:After treatment, the symptom scores for both rhinitis and asthma in the observation group were significantly lower than those in the control group [(3.65 ± 0.88) vs. (4.55 ± 1.06), t = 4.88, P < 0.001; (2.15 ± 0.56) vs. (3.28 ± 0.89), t = 7.86, P < 0.001]. The levels of immunoglobulin E, interleukin-4, and interleukin-6 in the observation group were significantly lower than those in the control group [(0.31 ± 0.18) g/L vs. (0.42 ± 0.19) g/L, t = 3.18, P = 0.002; (56.83 ± 8.25) ng/L vs. (62.16 ± 9.94) ng/L, t = 3.08, P = 0.003; (32.48 ± 3.11) ng/L vs. (39.61 ± 4.72) ng/L, t = 9.26, P < 0.001]. The values for forced expiratory volume in the first second and forced expiratory flow at 25%, 50%, and 75% of vital capacity in the observation group were significantly higher than those in the control group [(87.18 ± 5.15)% vs. (84.36 ± 4.68)%, t = 3.10, P = 0.002; (89.35 ± 3.88)% vs. (83.25 ± 3.56)%, t = 8.86, P < 0.001; (74.36 ± 6.65)% vs. (65.25 ± 5.36)%, t = 8.26, P < 0.001; (71.68 ± 8.76)% vs. (65.35 ± 7.86)%, t = 4.12, P < 0.001; (69.24 ± 4.38)% vs. (65.35 ± 2.43)%, t = 6.20, P < 0.001]. The incidence of adverse reactions was significantly higher in the observation group than in the control group [8.16% (4/49) vs. 4.29% (3/70), χ2 = 0.60, P = 0.439]. The overall response rate was significantly higher in the observation group than in the control group [95.92% (47/49) vs. 82.86% (58/70), χ2 = 5.26, P = 0.022]. Conclusions:Fluticasone propionate combined with loratadine syrup and montelukast sodium can effectively alleviate symptoms in children with asthma and allergic rhinitis, improve serum indicators, enhance lung function, and increase clinical efficacy without substantially increasing adverse reactions, demonstrating high safety.

Reducing the level of emotional expression conflict of patients is of great significance to promote the functional recovery of breast cancer patients,improve their prognosis and improve their quality of life.We introduce the research progress of ambivalence over emotional expression in breast cancer patients in terms of the connotation,measurement tools,influencing factors,and intervention methods.There is still a lack of research on measuring the emotional expression conflict of breast cancer patients in China,and it is still necessary to develop a measurement tool with cultural characteristics to obtain the true level of emotional expression conflict of patients.In clinical practice,complementary and alternative medicine,cognitive behavioral intervention,mindfulness training,expressive writing intervention,and other intervention strategies have achieved certain results in improving patients'negative emotions,but personalized intervention strategies still need further exploration.

Objective To investigate the clinical effect and survival quality of raltitrexed and radiotherapy in treatment of esophagus cancer. Methods 100 cases with esophagus cancer were selected. There were 50 cases using raltitrexed combined with concurrent radiotherapy as observation group. Others were treated with 5-Fu combined with concurrent radiotherapy as control group. The clinical therapeutic effect and survival situation of two groups were evaluated. Results After treatment, the total response rate of observation group (86.0%) was higher than control group (58.0%), the differences between the two groups was statistical difference(P<0.05).The one- and two-year survival rates in observation group were higher than control group (χ2 = 4.32, 7.954, P=0.038, 0.005<0.05).There was no significant difference between the two groups in incidence rate of acute esophagitis, acute bone marrow suppression and acute skin reaction. Conclusion The clinical therapy of raltitrexed plus radiotherapy in treatment of esophagus cancer is distinct, and improve the survival time and the quality of life of patients.

Aim: To establish a linear additive model for the predication of in vitro sinomenine hydrochloride release from the combination of immediate release, enteric-coated and sustained-release pellets based on the release profiles of each pellet type. Methods: Immediate release pellets were manufactured by extrusion/spher-onization technology. The operation of bottom-spraying in the fluid-bed equipment was conducted to enteric-coating using Eudragit~(R) L-30D-55 and sustained-release coating using Surelease~(R) . In vitro sinomenine hydrochloride release profiles of both uncoated and coated pellets were fitted to the chosen mathematical equations offered by the curve fitting toolbox of Matlab~(R) before a linear additive model was created based upon the best-to-fitting equations. The proportion of each pellet type in the combined format to generate the desired 24 h sinomenine hydrochloride release profile was solved by Matlab~(R). The predicted and assayed sinomenine hydrochloride release from the polled pellets was compared. Results: It was shown that the actual sinomenine hydrochloride release profiles of each pellet type were approximate to those of predicted ones. A linear additive model of the appropriate mathematical equations of each pellet was proven to be capable of controlling in vitro release of sinomenine hydrochloride multiple-unit pellets. Conclusion: A multiple-unit combined system of the selected pellets, as a novel sustained-release system, was successfully prepared. In vitro release performance of the calculated combination of each pellet type could be guaranteed by this approach in designing sustained-release drug delivery system.